Vaxcyte doses first subject in pneumococcal conjugate vaccine trial in infants

Vaxcyte doses first subject in pneumococcal conjugate vaccine trial in infants

Submitted by admin on December 4, 2024 - 9:59am
Source: 
Clinical Trials Arena
News Tags: 
Vaxcyte
clincal trials
VAX-31
vaccines
pneumococcal disease
Headline: 
Vaxcyte doses first subject in pneumococcal conjugate vaccine trial in infants
snippet: 

Vaxcyte has commenced the Phase II trial of its 31-valent pneumococcal conjugate vaccine (PCV) candidate, VAX-31, in healthy infants, with the first subjects receiving the dose.

Do Not Allow Advertisers to Use My Personal information